sirolimus and Osteonecrosis

sirolimus has been researched along with Osteonecrosis* in 5 studies

Reviews

1 review(s) available for sirolimus and Osteonecrosis

ArticleYear
Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients.
    The American journal of medicine, 2016, Volume: 129, Issue:6

    The success of organ transplantation allows many transplant recipients to return to life similar to nontransplant patients. Their need for regular health care, including preventive medicine, has switched the majority of responsibilities for their health care from transplant specialists to primary care physicians. To take care of transplant recipients, it is critical for primary care physicians to be familiar with immunosuppressive medications, their side effects, and common complications in transplant recipients. Ten subjects are reviewed here in order to assist primary care physicians in providing optimal care for transplant recipients.

    Topics: Adrenal Cortex Hormones; Contraceptive Agents, Female; Cyclosporine; Diarrhea; Drug Interactions; Drug Monitoring; Elective Surgical Procedures; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Medication Adherence; Mycophenolic Acid; Organ Transplantation; Osteonecrosis; Polycythemia; Pregnancy; Pregnancy Complications; Primary Health Care; Sirolimus; Tacrolimus; Transplant Recipients; Urinary Tract Infections

2016

Other Studies

4 other study(ies) available for sirolimus and Osteonecrosis

ArticleYear
Osteonecrosis of the jaw related to everolimus: a case report.
    The British journal of oral & maxillofacial surgery, 2013, Volume: 51, Issue:8

    Antiresorptive agent-related osteonecrosis of the jaw results in appreciable morbidity in affected patients. Nowadays many physicians prescribe an antiangiogenic agent for the management of malignant metastases. Everolimus is a serine-threonine kinase that acts as an inhibitor of mammalian target of rapamycin, which results in reduced growth of cells, angiogenesis, and survival of cells. We report the first case to our knowledge of osteonecrosis of the jaw that seemed to result from the additive effect of everolimus.

    Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Everolimus; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Sirolimus; Thyroid Neoplasms; Thyroidectomy; Zoledronic Acid

2013
Symptomatic osteonecrosis of the femoral head after adult orthotopic liver transplantation.
    Chinese medical journal, 2012, Volume: 125, Issue:14

    With the increase of survival in liver transplantation recipients, more patients are at a high risk of developing osteonecrosis, especially in the femoral head, due to immunosuppressive treatment. The purpose of this study was to report the incidence, possible risk factors, and outcome of symptomatic osteonecrosis of the femoral head (ONFH) in adult patients with current immunosuppressive agents and individual protocol after liver transplantation in China.. A retrospective analysis was performed on 226 adult patients who underwent orthotopic liver transplantation (OLT) at a single liver transplantation institution between January 2004 and December 2008. The posttransplant survival time (or pre-retransplantation survival time) of all the patients were more than 24 months. The possible pre- and post-transplantation risk factors of symptomatic ONFH were investigated and the curative effects of the treatment were also reported.. The incidence of ONFH was 1.33% in patients after OLT. ONFH occurred at a mean of (14 ± 6) months (range, 10 - 21 months) after transplantation. Male patients more often presented with osteonecrosis as a complication than female patients. The patients with lower pre-transplantation total bilirubin and direct bilirubin levels (P < 0.05). There was no difference in the cumulative dose of corticosteroids or tacrolimus between the patients with or without symptomatic ONFH. Patients were treated either pharmacologically or surgically. All patients showed a nice curative effect without major complications during the 18 - 63 months post-treatment follow up.. The symptomatic ONFH does not occur commonly after adult OLT in the current individual immunosuppressive protocol in China.

    Topics: Adult; Aged; Cyclosporine; Female; Femur Head Necrosis; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Methylprednisolone; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Sirolimus; Tacrolimus; Young Adult

2012
Bone disease in renal transplantation and pleotropic effects of vitamin D therapy.
    Transplantation proceedings, 2010, Volume: 42, Issue:7

    Osteoporosis, osteopenia, and osteonecrosis are common in renal transplant recipients. In this study, we evaluated relationship between bone mineral density (BMD) and posttransplant duration; creatinine clearance; serum levels of glucose, calcium, phosphorus, alkaline phosphatase, vitamin D (vitD), parathormone, magnesium, C telopeptide, osteocalcin, lipids, and vit D therapy. Eighty five subjects included in this study had a mean age of 36.25 ± 10.5 years. At least at 6-month intervals we measured femoral neck (FN) and lumbar vertebra (LV) by DEXA and biochemical parameters. VitD was prescribed in 57 patients (vitDG). The mean duration of posttransplantation follow-up was 9.82 ± 2.72 months. T scores (TS) of FN and LV were normal in 29.4% and 21.2%; osteopenia in 56.5% and 49.4%; and osteoporosis in 12.1% and 29.4% of patients, respectively. Upon follow-up, TS improved significantly from -1.58 to -1.46 in FN and from -1.88 to -1.70 in LV (P < .05 for both). In patients receiving vitDG, TS improved significantly from -1.74 to -1.61 on FN and from -2.16 to -1.97 on LV (P < .05 for both). Osteocalcin and vitDG levels decreased in all patients (P < .05 for all). Blood urea nitrogen and serum creatinine increased (P < .05). In VitDG cohort, triglyceride levels decreased (P < .05) with unchanged blood glucose values; but among the other patients, triglycerides were unchanged but glucose levels had increased (P < .05). Bone disease including osteopenia or osteoporosis was observed among 70%. During the follow-up period, BMD increased significantly from baseline at 9.82 ± 2.72 months. VitD therapy caused more prominent improvements in BMD and decreases in serum triglycerides as well as mutigated the increase in blood glucose.

    Topics: Azathioprine; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Creatinine; Female; Humans; Kidney Transplantation; Lipids; Male; Methylprednisolone; Mycophenolic Acid; Osteonecrosis; Osteoporosis; Sirolimus; Vitamin D

2010
Drug points: Premature osteonecrosis and sirolimus treatment in renal transplantation.
    BMJ (Clinical research ed.), 2001, Sep-22, Volume: 323, Issue:7314

    Topics: Adult; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Osteonecrosis; Sirolimus

2001